Published in Liver Int on April 16, 2012
Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol (2014) 0.88
Cirrhotic Multiorgan Syndrome. Dig Dis Sci (2015) 0.82
Comorbidity in cirrhosis. World J Gastroenterol (2014) 0.80
Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther (2014) 0.80
Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int (2014) 0.79
Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One (2016) 0.75
Influencing factors of transient elastography in detecting liver stiffness. Exp Ther Med (2016) 0.75
Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome. World J Gastrointest Pharmacol Ther (2015) 0.75
Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis-the first 24 h. Frontline Gastroenterol (2014) 0.75
Comprehensive review of post-liver resection surgical complications and a new universal classification and grading system. World J Hepatol (2014) 0.75
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11
Rifaximin treatment in hepatic encephalopathy. N Engl J Med (2010) 9.60
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology (2008) 3.26
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97
SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine. Nature (2013) 2.52
Prospective comparison of patient experience with colon imaging tests. Am J Med (2006) 2.42
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int (2014) 2.23
Liver transplantation for patients with alcoholic liver disease: an open question. Dig Liver Dis (2011) 2.14
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 2.11
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol (2002) 2.01
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol (2012) 2.00
Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol (2002) 1.85
Liver transplantation: the last measure in the treatment of bile duct injuries. World J Surg (2008) 1.84
Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol (2004) 1.83
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol (2010) 1.70
The hepatic apelin system: a new therapeutic target for liver disease. Hepatology (2008) 1.67
Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. J Hepatol (2004) 1.67
AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol (2007) 1.63
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol (2008) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int (2012) 1.56
Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology (2004) 1.56
Post-paracentesis circulatory derangements are related to monocyte activation. Liver Int (2014) 1.47
The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int (2009) 1.46
Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. J Gastroenterol Hepatol (2005) 1.45
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study. J Clin Gastroenterol (2010) 1.45
Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut (2010) 1.44
Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol (2011) 1.44
Increased number and function of endothelial progenitor cells stimulate angiogenesis by resident liver sinusoidal endothelial cells (SECs) in cirrhosis through paracrine factors. J Hepatol (2012) 1.42
Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol (2003) 1.36
Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 1.33
Endoscopic biliary drainage for severe acute cholangitis in biliary obstruction as a result of malignant and benign diseases. J Gastroenterol Hepatol (2004) 1.32
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut (2010) 1.29
An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol (2008) 1.27
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol (2010) 1.22
Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol (2006) 1.20
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology (2012) 1.20
Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis (2009) 1.18
Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology (2013) 1.17
Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol (2010) 1.17
Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer (2010) 1.15
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol (2007) 1.14
Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet (2002) 1.11
The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol (2011) 1.11
Endoscopic management of postoperative bile leaks. Hepatobiliary Pancreat Dis Int (2006) 1.10
A novel model of CCl4-induced cirrhosis with ascites in the mouse. J Hepatol (2009) 1.10
Posttransplantation lymphoproliferative disorders. Arch Intern Med (2003) 1.09
Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol (2013) 1.08
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol (2006) 1.08
The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology (2013) 1.08
Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol (2006) 1.08
Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J Gastroenterol Hepatol (2007) 1.08
The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J Hepatol (2011) 1.07
Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl (2005) 1.06
Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int (2008) 1.05
The reduced tolerance of rat fatty liver to ischemia reperfusion is associated with mitochondrial oxidative injury. J Surg Res (2005) 1.05
Interactions of the heart and the liver. Eur Heart J (2013) 1.04
Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2010) 1.03
Endoscopic management of acute cholangitis in elderly patients. World J Gastroenterol (2006) 1.02
The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One (2011) 1.02
Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol (2004) 1.01
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. Stem Cells (2006) 1.01
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut (2011) 1.00
Alcohol use in adults. N Engl J Med (2013) 0.99
Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India. J Med Virol (2006) 0.98
Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med (2002) 0.98
The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab (2009) 0.97
Stem cells for end stage liver disease: how far have we got? World J Gastroenterol (2008) 0.96
Transmission of G145R mutant of HBV to an unrelated contact. J Med Virol (2005) 0.94
Baculovirus as mammalian cell expression vector for gene therapy: an emerging strategy. Mol Ther (2002) 0.94
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner? Liver Transpl (2010) 0.93
QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol (2003) 0.92
Endoscopic management of biliary complications after adult living-donor versus deceased-donor liver transplantation. Transplantation (2009) 0.92
Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol (2007) 0.92
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis. Lab Invest (2011) 0.92
Transient elastographic evaluation in adult subjects without overt liver disease: influence of alanine aminotransferase levels. J Gastroenterol Hepatol (2011) 0.91
Minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction. Am J Gastroenterol (2008) 0.91
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs (2015) 0.91
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy (2013) 0.91
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol (2007) 0.90
Clinical indications for the albumin use: still a controversial issue. Eur J Intern Med (2013) 0.90
Transmission of T. cruzi infection via liver transplantation to a nonreactive recipient for Chagas' disease. Liver Transpl (2005) 0.90
Cardiopulmonary complications in chronic liver disease. World J Gastroenterol (2006) 0.90
Liver cirrhosis and arterial hypertension. World J Gastroenterol (2006) 0.90
Management of acute hepatitis B and reactivation of hepatitis B. Liver Int (2013) 0.89
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol (2005) 0.89
Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology (2004) 0.89
Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology (2014) 0.88
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One (2013) 0.88
Role of contrast-enhanced ultrasonography in primary hepatic lymphoma. J Ultrasound Med (2010) 0.88